It occurred to me after several such events this year that virtual meetings create a very different pattern for spectators from live events where we all dash from one hall to another trying to optimise the viewing experience and catch as many key talks as we can.
Instead of the annual rugby scrum in the ASCO poster halls, we can imagine ourselves in an entirely different world with social distancing virtually
Many people will no doubt be eager to listen to the various oral presentations of phase 3 data come Friday morning, while the poor posters may well languish until some undetermined time later, so why not take a step back and highlight some of the early work in developmental therapeutics ahead of time?
In the final part of our ASCO Preview series, we offer our independent take and candid commentary on ten abstracts in developmental therapeutics to watch out for.
A word of warning – we don’t take a particular perspective through the lens of rose tinted glasses, so not all the analyses are positive and there are some firm words against some of the selections regarding continued development or the researchers conclusions/recommendations.
Some of these are agents in early development, some are biomarkers or even emerging trends, but all are intriguing in their own unique fashion.
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ASCO meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
ASGCT Virtual: We are thoroughly enjoying the “live” annual meeting of the American Society of Gene and Cell Therapy (ASGCT).
Unlike other virtual meetings that have recorded presentations, ASGCT are running a live format, with presenters giving their talks in real-time from wherever in the world they may be. By and large this has worked well, and it definitely felt as though you were at the meeting.
We are also enjoying the ePoster hall, and in particular, the short audio tour that many presenters have made to take you through their poster. Obviously, it’s not a substitute for in-person contact, but who would want to be in a crowded poster hall or meeting room in these uncertain times with the potential for the coronavirus lurking about?
Earlier today we “attended” a virtual ASGCT20 scientific session with oral presentations organized by the American Society for Transplantation and Cellular Therapy (ASTCT) on Engineering Immunity.
Four speakers focused on CAR T cell therapy in non-B cell malignancies – what did we learn? It turns out the answer was quite a bit!
To find out more about our oncology analysis and get a heads up on insights and commentary emerging from the ASGCT meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.